Your browser doesn't support javascript.
loading
National Chlamydia Screening Rate in Young Sexually Active Women Using HEDIS Measures in the United States, 2011 to 2020.
He, Larry; Patel, Chirag; Tao, Guoyu.
Afiliación
  • Patel C; Centers for Disease Control and Prevention, Atlanta, GA.
  • Tao G; Centers for Disease Control and Prevention, Atlanta, GA.
Sex Transm Dis ; 50(7): 415-419, 2023 07 01.
Article en En | MEDLINE | ID: mdl-36943794
BACKGROUND: National guidelines recommend sexually active women younger than 25 years be screened annually for chlamydia. Our objective was to estimate the chlamydia screening rate of sexually active women aged 16 to 24 years from 2011 to 2020. METHODS: We analyzed the chlamydia screening rates among sexually active women aged 16 to 24 years from 2011 to 2020 using the chlamydia measures in the Healthcare Effectiveness Data and Information Set data set. The annual national chlamydia screening rates were further stratified by census region and by patient age. RESULTS: Chlamydia screening rates among sexually active women aged 16 to 24 years ranged from 55.0% to 61.8% in Medicaid health plans and from 46.9% to 52.4% in commercial health plans during 2011-2020. The Northeast consistently had the highest screening rates among 4 geographic regions. The chlamydia screening rate among sexually active women aged 16 to 24 years decreased from 2019 to 2020: from 61.8% to 57.9% in Medicaid plans and from 52.4% to 48.4% in commercial health plans. The number of sexually active women aged 16 to 24 years covered by commercial health plans decreased from 2019 to 2020, but the number covered by Medicaid increased from 2019 to 2020. CONCLUSIONS: The chlamydia screening rates in the target population have increased little from 2011 to 2019. The decrease in chlamydia screening rates between 2019 and 2020 could be related to the COVID-19 pandemic and the reduced use of health services during that period. With recently suboptimal chlamydia screening rates in the United States, interventions of improving and assessing chlamydia screening rates are needed.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Infecciones por Chlamydia / COVID-19 Tipo de estudio: Diagnostic_studies / Prognostic_studies / Screening_studies Límite: Female / Humans País/Región como asunto: America do norte Idioma: En Revista: Sex Transm Dis Año: 2023 Tipo del documento: Article Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Infecciones por Chlamydia / COVID-19 Tipo de estudio: Diagnostic_studies / Prognostic_studies / Screening_studies Límite: Female / Humans País/Región como asunto: America do norte Idioma: En Revista: Sex Transm Dis Año: 2023 Tipo del documento: Article Pais de publicación: Estados Unidos